- Press Release -

Rockville, Md. The global liver cancer diagnostics market is set to expand at a 5.5% CAGR through 2022, according to Fact.MR, as one of the world's deadliest cancers keeps demand for testing firm. Liver cancer ranked as the fifth most prevalent cancer and accounted for a large share of cancer deaths, and its aggressiveness and poor survival rate have made early, accurate diagnosis a priority.

North America carries the market, AFP tests lead by type, and hospital-associated labs handle most testing. Because many of the disease's risk factors can be managed, from hepatitis infection to obesity and alcohol-related cirrhosis, prevention and screening are widening the diagnostic funnel.

Tests, Settings and Regions

AFP testing remains the most sought-after approach, holding more than half of revenue in 2017 and picking up further share by 2022. The fastest growth belongs to biopsy tests, followed by liver function tests, as clinicians push for more definitive results. By setting, hospital-associated labs are the leading end user and carry the largest revenue, independent diagnostic laboratories rank second, and cancer research institutes grow the quickest.

North America stays the most lucrative region, Europe tracks a similar growth rate, and Japan and the Middle East and Africa remain subdued through the forecast period.

Prevention and Screening Drive Demand

The market's direction is shaped by both risk and response. Modifiable risk factors such as hepatitis B and C, diabetes, obesity and alcohol-induced cirrhosis open the door to prevention through lifestyle change and immunisation, while advances in treatment, from safer liver transplants to partial hepatectomy, reinforce the case for early diagnosis. Research institutes developing improved tests keep the pipeline moving.

Suppliers and Their Playbook

The field brings together sequencing, molecular diagnostics and liquid biopsy specialists.

• Illumina, Inc., Sysmex Corporation, Danaher Corporation, Biocept, Inc., and Foundation Medicine, Inc. are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, growth favours AFP and biopsy capability alongside screening-oriented tests. Investors get a market with a firm clinical tailwind and steady growth. Procurement and lab teams can plan around hospital labs leading demand, AFP carrying volume, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global liver cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the liver cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.